8-K - Brainstorm Cell Therapeutics Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Securities Issuance

Exhibits On

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On December 31, 2025, January 5, 2026 and January 6, 2026, Brainstorm Cell Therapeutics Inc. (the “ Company ”) enter

Material Agreement

$94.3K$12.3K$82.0K$2.0M

Source Document

3.02

Unregistered Sales of Equity Securities. The Notes, and the shares of the Company’s common stock issuable upon conversion of the Notes, if any, were or will be

Securities Issuance

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Securities Purchase Agreement, dated December 31, 2025, by and between the Company

Exhibits Only

Exhibits (7)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

10.3

EXHIBIT 10.3

10.4

EXHIBIT 10.4

10.5

EXHIBIT 10.5

10.6

EXHIBIT 10.6

8-K

FORM 8-K